TCT-993 Comparison of Outcomes in Patients With and Without Chronic Kidney Disease Undergoing Transcatheter Tricuspid Valve Replacement (TTVR)

Authors

Sahar Razmjou, Henry Ford HealthFollow
Brian O'Neill, Henry Ford HealthFollow
Tiberio Frisoli, Henry Ford HealthFollow
Pedro Engel Gonzalez, Henry Ford HealthFollow
James Lee, Henry Ford HealthFollow
John Dawdy, Henry Ford HealthFollow
Nathaniel Bowerman, Henry Ford HealthFollow
Pedro Villablanca, Henry Ford HealthFollow

Recommended Citation

Razmjou S, O'Neill B, Frisoli T, Engel Gonzalez P, Lee J, Dawdy J, Bowerman N, Villablanca P. TCT-993 Comparison of Outcomes in Patients With and Without Chronic Kidney Disease Undergoing Transcatheter Tricuspid Valve Replacement (TTVR). J Am Coll Cardiol 2025; 86(17):B424.

Document Type

Conference Proceeding

Publication Date

10-28-2025

Publication Title

J Am Coll Cardiol

Abstract

Background: Patients with chronic kidney disease (CKD), including those on end-stage renal disease (ESRD), undergoing transcatheter tricuspid valve replacement (TTVR) may be at increased risk of adverse outcomes. This study aims to compare clinical outcomes following TTVR in patients with versus without CKD/ESRD. Methods: We analyzed 112 patients who underwent TTVR for TR. Patients were stratified into two cohorts: CKD/ESRD (n=18) and no CKD/ESRD (n=94). Baseline characteristics and clinical outcomes were compared, including functional status, residual TR, and major adverse events. Results: Patients with CKD/ESRD were younger (74.5 ± 6.5 vs. 78.8 ± 9.8 years) and had a higher mean BMI (30.2± 5.3 vs. 27.7 ± 5.9). Baseline NYHA class III/IV and TR severity were similar across groups. At 30 days follow-up, all-cause mortality was slightly higher in the CKD/ESRD group (5.6% vs. 2.1%). Residual TR reduction was achieved in 100% of CKD/ESRD and 97% of no-CKD/ESRD patients. CKD/ESRD patients had a higher rate of bleeding (38.9% vs. 27.7% p=0.39) and new pacemaker implantation (22.2% vs. 8.5% p=0.08). Functional outcomes were comparable overall, although a greater proportion of CKD/ESRD patients remained in NYHA class III/IV at follow-up (28.6% vs. 20.0%). KCCQ-OS scores were similar between groups (59.8 ± 20.7 vs. 63.3 ± 24.2). [Formula presented] Conclusion: TTVR in patients with CKD/ESRD appears to provide comparable functional improvement as in those without CKD. However, the CKD/ESRD group showed a trend toward higher bleeding rates and pacemaker implantation, underscoring the need for individualized risk assessment and clinical management. Categories: STRUCTURAL: Valvular Disease and Intervention: Tricuspid

Volume

86

Issue

17

First Page

B424